Pulmonary arterial hypertension affects 1.1% of adults with congenital heart disease in Australia
A national study in ERJ Open Research reports that clinically significant pulmonary arterial hypertension affects a small proportion of Australian adults with congenital heart disease, and that over 35% died during follow-up.
“Clinically significant pulmonary arterial hypertension affects a small but significant proportion (1.1%) of adults with congenital heart disease in Australia.”— ERS publications
Clinically significant pulmonary arterial hypertension (PAH) affects 1.1% of adults with congenital heart disease in Australia, according to a national study in ERJ Open Research.
The findings were summarised in a post on X by ERS publications, whose profile lists journals including the European Respiratory Journal, ERJ Open Research and Breathe. The post described the proportion of affected adults as "small but significant".
According to the post, the national study involved 392 patients. It stated that over 35% of patients died during follow-up.
The post did not give further detail on the study design, the length of follow-up or the characteristics of the patients. It linked to additional material, which was not included in the source text used for this article.
Original source
“Clinically significant pulmonary arterial hypertension affects a small but significant proportion (1.1%) of adults with congenital heart disease in Australia.”
— ERS publications View the post on X
